Importantly, in contrast to recent studies of systemic DLBCL [10]–[12], we did not find any association of MYC expression, MYC/BCL2 coexpression, or COO subtype with adverse clinical features or survival. Here, BCL2 is linked to diffuse large B-cell lymphoma.